Cumberland Net Working Capital vs Net Tangible Assets Analysis

CPIX Stock

USD 1.76 0.06 3.53%

Cumberland Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cumberland Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cumberland Pharmaceuticals is a good investment. Please check the relationship between Cumberland Pharmaceuticals Net Working Capital and its Net Tangible Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

Net Working Capital vs Net Tangible Assets

Net Working Capital vs Net Tangible Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cumberland Pharmaceuticals Net Working Capital account and Net Tangible Assets. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Cumberland Pharmaceuticals' Net Working Capital and Net Tangible Assets is 0.93. Overlapping area represents the amount of variation of Net Working Capital that can explain the historical movement of Net Tangible Assets in the same time period over historical financial statements of Cumberland Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cumberland Pharmaceuticals' Net Working Capital and Net Tangible Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Working Capital of Cumberland Pharmaceuticals are associated (or correlated) with its Net Tangible Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Tangible Assets has no effect on the direction of Net Working Capital i.e., Cumberland Pharmaceuticals' Net Working Capital and Net Tangible Assets go up and down completely randomly.

Correlation Coefficient

0.93

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Working Capital

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Most indicators from Cumberland Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cumberland Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.Discontinued Operations is likely to rise to about 2.4 M in 2024, whereas Selling General Administrative is likely to drop slightly above 8.9 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	98.0K	586.0K	667.9K	701.3K
Depreciation And Amortization	6.8M	5.4M	5.8M	6.1M

Interest Expense Depreciation And Amortization

Cumberland Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Non Currrent Assets Other	Other Liab
Total Assets		0.39	0.53	0.48	0.64	0.09	0.87	-0.23	0.39	0.33	0.5	0.49	0.5	0.49	0.1	0.37	0.54	0.57	-0.09	0.43	0.05	0.75	0.17	0.66	0.18	0.13
Short Long Term Debt Total	0.39		0.7	0.92	-0.44	0.6	0.38	0.69	-0.59	0.83	-0.39	0.87	-0.53	0.75	-0.65	0.99	0.58	0.64	0.17	0.98	0.53	-0.22	-0.22	0.76	0.77	0.89
Other Current Liab	0.53	0.7		0.87	-0.14	0.4	0.49	0.45	-0.25	0.62	-0.26	0.73	-0.26	0.74	-0.47	0.71	0.64	0.5	0.25	0.79	0.35	0.04	-0.14	0.82	0.34	0.57
Total Current Liabilities	0.48	0.92	0.87		-0.34	0.55	0.48	0.67	-0.46	0.86	-0.42	0.93	-0.48	0.82	-0.7	0.92	0.58	0.58	0.33	0.97	0.49	-0.17	-0.12	0.9	0.69	0.81
Total Stockholder Equity	0.64	-0.44	-0.14	-0.34		-0.38	0.53	-0.82	0.85	-0.38	0.87	-0.29	0.96	-0.18	0.68	-0.47	0.02	0.05	-0.3	-0.42	-0.36	0.94	0.33	-0.05	-0.43	-0.61
Property Plant And Equipment Net	0.09	0.6	0.4	0.55	-0.38		0.41	0.63	-0.76	0.72	-0.39	0.54	-0.48	0.54	-0.62	0.53	-0.02	0.31	0.13	0.55	0.99	-0.31	-0.41	0.3	0.79	0.7
Current Deferred Revenue	0.87	0.38	0.49	0.48	0.53	0.41		-0.1	0.14	0.5	0.4	0.5	0.38	0.51	-0.09	0.33	0.28	0.57	-0.05	0.4	0.41	0.6	0.1	0.57	0.39	0.22
Net Debt	-0.23	0.69	0.45	0.67	-0.82	0.63	-0.1		-0.85	0.74	-0.91	0.64	-0.93	0.4	-0.93	0.69	0.26	0.06	0.56	0.7	0.6	-0.74	-0.4	0.48	0.71	0.88
Retained Earnings	0.39	-0.59	-0.25	-0.46	0.85	-0.76	0.14	-0.85		-0.63	0.73	-0.39	0.87	-0.35	0.76	-0.58	-0.03	-0.16	-0.18	-0.54	-0.75	0.74	0.46	-0.13	-0.69	-0.8
Accounts Payable	0.33	0.83	0.62	0.86	-0.38	0.72	0.5	0.74	-0.63		-0.46	0.8	-0.53	0.73	-0.84	0.8	0.42	0.53	0.34	0.84	0.7	-0.23	-0.07	0.71	0.81	0.86
Cash	0.5	-0.39	-0.26	-0.42	0.87	-0.39	0.4	-0.91	0.73	-0.46		-0.42	0.95	-0.15	0.81	-0.42	-0.06	0.25	-0.65	-0.43	-0.37	0.88	0.39	-0.27	-0.47	-0.63
Non Current Assets Total	0.49	0.87	0.73	0.93	-0.29	0.54	0.5	0.64	-0.39	0.8	-0.42		-0.47	0.75	-0.68	0.87	0.42	0.49	0.37	0.92	0.47	-0.21	-0.18	0.91	0.8	0.77
Cash And Short Term Investments	0.5	-0.53	-0.26	-0.48	0.96	-0.48	0.38	-0.93	0.87	-0.53	0.95	-0.47		-0.27	0.82	-0.55	-0.06	0.05	-0.44	-0.53	-0.46	0.92	0.39	-0.25	-0.59	-0.73
Net Receivables	0.49	0.75	0.74	0.82	-0.18	0.54	0.51	0.4	-0.35	0.73	-0.15	0.75	-0.27		-0.46	0.74	0.33	0.67	0.04	0.79	0.46	-0.02	-0.01	0.68	0.57	0.55
Common Stock Shares Outstanding	0.1	-0.65	-0.47	-0.7	0.68	-0.62	-0.09	-0.93	0.76	-0.84	0.81	-0.68	0.82	-0.46		-0.65	-0.21	-0.21	-0.58	-0.68	-0.61	0.62	0.13	-0.57	-0.73	-0.82
Non Current Liabilities Total	0.37	0.99	0.71	0.92	-0.47	0.53	0.33	0.69	-0.58	0.8	-0.42	0.87	-0.55	0.74	-0.65		0.61	0.62	0.18	0.98	0.46	-0.25	-0.24	0.76	0.73	0.89
Inventory	0.54	0.58	0.64	0.58	0.02	-0.02	0.28	0.26	-0.03	0.42	-0.06	0.42	-0.06	0.33	-0.21	0.61		0.36	0.09	0.61	-0.05	0.28	-0.1	0.64	0.09	0.51
Other Current Assets	0.57	0.64	0.5	0.58	0.05	0.31	0.57	0.06	-0.16	0.53	0.25	0.49	0.05	0.67	-0.21	0.62	0.36		-0.38	0.62	0.27	0.26	0.24	0.49	0.34	0.37
Other Stockholder Equity	-0.09	0.17	0.25	0.33	-0.3	0.13	-0.05	0.56	-0.18	0.34	-0.65	0.37	-0.44	0.04	-0.58	0.18	0.09	-0.38		0.25	0.13	-0.38	0.01	0.4	0.26	0.29
Total Liab	0.43	0.98	0.79	0.97	-0.42	0.55	0.4	0.7	-0.54	0.84	-0.43	0.92	-0.53	0.79	-0.68	0.98	0.61	0.62	0.25		0.49	-0.22	-0.19	0.84	0.73	0.87
Property Plant And Equipment Gross	0.05	0.53	0.35	0.49	-0.36	0.99	0.41	0.6	-0.75	0.7	-0.37	0.47	-0.46	0.46	-0.61	0.46	-0.05	0.27	0.13	0.49		-0.29	-0.38	0.24	0.75	0.66
Total Current Assets	0.75	-0.22	0.04	-0.17	0.94	-0.31	0.6	-0.74	0.74	-0.23	0.88	-0.21	0.92	-0.02	0.62	-0.25	0.28	0.26	-0.38	-0.22	-0.29		0.33	0.05	-0.4	-0.43
Short Term Debt	0.17	-0.22	-0.14	-0.12	0.33	-0.41	0.1	-0.4	0.46	-0.07	0.39	-0.18	0.39	-0.01	0.13	-0.24	-0.1	0.24	0.01	-0.19	-0.38	0.33		-0.01	-0.35	-0.44
Intangible Assets	0.66	0.76	0.82	0.9	-0.05	0.3	0.57	0.48	-0.13	0.71	-0.27	0.91	-0.25	0.68	-0.57	0.76	0.64	0.49	0.4	0.84	0.24	0.05	-0.01		0.54	0.62
Non Currrent Assets Other	0.18	0.77	0.34	0.69	-0.43	0.79	0.39	0.71	-0.69	0.81	-0.47	0.8	-0.59	0.57	-0.73	0.73	0.09	0.34	0.26	0.73	0.75	-0.4	-0.35	0.54		0.83
Other Liab	0.13	0.89	0.57	0.81	-0.61	0.7	0.22	0.88	-0.8	0.86	-0.63	0.77	-0.73	0.55	-0.82	0.89	0.51	0.37	0.29	0.87	0.66	-0.43	-0.44	0.62	0.83

Click cells to compare fundamentals

Cumberland Pharmaceuticals Account Relationship Matchups

Cumberland Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Short Long Term Debt Total	21.5M	17.1M	16.1M	21.0M	18.4M	11.9M
Other Current Liab	7.7M	11.3M	8.7M	17.6M	13.6M	7.8M
Total Current Liabilities	24.2M	25.7M	19.3M	28.6M	28.0M	16.8M
Total Stockholder Equity	51.1M	47.0M	42.8M	36.3M	29.6M	58.3M
Property Plant And Equipment Net	3.7M	2.6M	1.5M	5.5M	7.0M	7.4M
Net Debt	(6.7M)	(7.7M)	(11.0M)	1.2M	106.9K	112.2K
Retained Earnings	1.2M	(2.1M)	(5.6M)	(11.2M)	(17.5M)	(16.6M)
Accounts Payable	10.0M	13.4M	9.6M	10.8M	14.0M	14.7M
Cash	28.2M	24.8M	27.0M	19.8M	18.3M	27.3M
Non Current Assets Total	54.4M	46.5M	38.8M	47.1M	46.1M	27.5M
Cash And Short Term Investments	28.2M	24.8M	27.0M	19.8M	18.3M	31.1M
Net Receivables	7.9M	12.4M	6.9M	13.2M	9.8M	7.4M
Common Stock Shares Outstanding	15.4M	15.2M	14.9M	14.6M	14.3M	13.5M
Liabilities And Stockholders Equity	104.5M	96.5M	84.5M	92.9M	81.8M	88.1M
Non Current Liabilities Total	29.3M	23.9M	22.6M	28.4M	24.5M	13.1M
Inventory	8.9M	10.6M	8.4M	9.4M	4.6M	7.3M
Other Current Assets	2.8M	2.2M	3.3M	3.5M	3.0M	2.3M
Other Stockholder Equity	2.9M	3.1M	3.4M	(212.3K)	(244.2K)	(256.4K)
Total Liab	53.5M	49.6M	41.9M	57.0M	52.5M	29.9M
Property Plant And Equipment Gross	3.7M	2.6M	1.5M	5.5M	9.3M	9.7M
Total Current Assets	50.2M	50.0M	45.7M	45.9M	35.7M	60.5M
Intangible Assets	30.9M	28.1M	24.0M	30.6M	22.6M	19.2M
Non Currrent Assets Other	18.9M	14.9M	12.5M	10.0M	15.5M	16.3M
Other Liab	8.7M	7.9M	7.5M	7.6M	8.7M	9.2M
Other Assets	18.9M	17.8M	12.5M	10.0M	11.6M	7.4M
Long Term Debt	20M	18.5M	15M	16.2M	12.8M	9.3M
Common Stock	49.9M	49.1M	48.5M	47.5M	47.1M	44.7M
Property Plant Equipment	16.3M	12.2M	1.5M	5.5M	6.3M	6.6M
Net Tangible Assets	19.3M	18.0M	18.0M	4.8M	4.3M	4.1M
Noncontrolling Interest In Consolidated Entity	(198.6K)	(274.3K)	(37.6K)	(117.1K)	(105.4K)	(110.7K)
Common Stock Total Equity	52.4M	51.1M	49.9M	49.1M	44.2M	46.2M
Retained Earnings Total Equity	11.7M	4.7M	1.2M	(2.1M)	(1.9M)	(1.8M)
Long Term Debt Total	9.8M	20M	18.5M	15M	17.3M	10.8M

Pair Trading with Cumberland Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cumberland Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cumberland Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cumberland Stock

0.81	RZLT	Rezolute Financial Report 9th of May 2024	Pair Corr
0.78	SNDL	SNDL Inc Financial Report 20th of May 2024	Pair Corr
0.75	CGC	Canopy Growth Corp Financial Report 27th of June 2024	Pair Corr
0.74	ACB	Aurora Cannabis Sell-off Trend	Pair Corr
0.74	RVMD	Revolution Medicines Financial Report 13th of May 2024	Pair Corr

The ability to find closely correlated positions to Cumberland Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cumberland Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cumberland Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cumberland Pharmaceuticals to buy it.

The correlation of Cumberland Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cumberland Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cumberland Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cumberland Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cumberland Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cumberland Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cumberland Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cumberland Pharmaceuticals Stock:

How To Invest In Cumberland

Details

Is Cumberland Stock a good investment?

Details

What is Cumberland Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cumberland Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Cumberland Stock please use our How to Invest in Cumberland Pharmaceuticals guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Complementary Tools for Cumberland Stock analysis

When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Risk-Return Analysis View associations between returns expected from investment and the risk you assume

Is Cumberland Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cumberland Pharmaceuticals. If investors know Cumberland will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cumberland Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.44)

Revenue Per Share

2.766

Quarterly Revenue Growth

0.025

Return On Assets

(0.04)

Return On Equity

(0.19)

The market value of Cumberland Pharmaceuticals is measured differently than its book value, which is the value of Cumberland that is recorded on the company's balance sheet. Investors also form their own opinion of Cumberland Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cumberland Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cumberland Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cumberland Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cumberland Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cumberland Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cumberland Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cumberland Net Working Capital vs Net Tangible Assets Analysis

Net Working Capital vs Net Tangible Assets

Net Working Capital vs Net Tangible Assets Correlation Analysis

Correlation Coefficient

Net Working Capital

Net Tangible Assets

Cumberland Pharmaceuticals fundamental ratios Correlations

Cumberland Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cumberland Pharmaceuticals fundamental ratios Accounts

Pair Trading with Cumberland Pharmaceuticals

Moving against Cumberland Stock

Complementary Tools for Cumberland Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Liab	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Non Current Liabilities Total
Total Liab	+ 0.97	Total Current Liabilities
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity

Common Stock Shares Outstanding	- 0.93	Net Debt
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.91	Net Debt
Retained Earnings	- 0.85	Net Debt
Common Stock Shares Outstanding	- 0.84	Accounts Payable
Other Liab	- 0.82	Common Stock Shares Outstanding